Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07220060 plus fulvestrant vs endocrine-based therapy in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor
CTR20241432Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atirmociclib in breast cancer, sponsored by Pfizer. Started Apr 2024; status: terminated.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20241432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241432.